Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay

被引:3
作者
Castillo, Cecilia [1 ]
Camejo, Natalia [1 ]
Etcheverria, Cristian [2 ]
Ferradaz, Jessica [2 ]
Ferreira, Agustin [2 ]
Fontan, Analia [2 ]
Gabin, Ana Sofia [2 ]
Herrera, Guadalupe [3 ]
Artagaveytia, Nora [1 ]
Parma, Gabriel [4 ]
Delgado, Lucia [1 ]
机构
[1] Univ Republica, Hosp Clin Dr Manuel Quintela, Serv Oncol Clin, Montevideo, Uruguay
[2] Univ Uruguay, Sch Med, Montevideo, Uruguay
[3] Univ Uruguay, Sch Med, Dept Quantitat Methods, Montevideo, Uruguay
[4] Univ Rpubl, Ctr Cardiovasc Univ, Hosp Clin, Unidad Imagen Cardiaca, Montevideo, Uruguay
关键词
breast cancer; cardio-oncology; cardiac monitoring; cardiotoxicity; trastuzumab; ADJUVANT CHEMOTHERAPY;
D O I
10.1097/MD.0000000000029927
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This srudy aimed to estimate the prevalence of trastuzumab-induced cardiotoxicity in Uruguayan women diagnosed with human epidermal growth factor receptor 2 (HER2)-positive breast cancer over a 10-year period, who were treated under the financial coverage of the National Resources Fund (Fondo Nacional de Recursos). This was an observational, descriptive study based on the analysis of an anonymized database of Uruguayan women diagnosed with HER2-positive breast cancer who received adjuvant trastuzumab treatment from to 2006 to 2016, provided by the Fondo Nacional de Recursos. Statistical analysis was performed using SPSS Statistics version 25, and variables were assessed using measures of central tendency, dispersion, contingency tables, and proportions. The chi-square test was used to analyze the association between the different variables. The study included 1401 patients diagnosed with stage I to III HER2-positive breast cancer. The mean age at diagnosis was 52 years. The prevalence of cardiotoxicity was 20.3%. Most patients who discontinued treatment owing to cardiotoxicity eventually resumed treatment (92.6%). Moreover, the prevalence of cardiotoxicity was similar among patients who received regimens with and without anthracyclines. No association was observed between prior cardiovascular events or trastuzumab administration (concurrent vs sequential) and the development of cardiotoxicity. In the present study, the prevalence of cardiotoxicity was similar to that reported nationally and internationally. Most patients did not develop cardiotoxicity, while the ones who developed it remained asymptomatic and cardiotoxicity was reversible.
引用
收藏
页数:5
相关论文
共 22 条
  • [1] Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database
    Anderson, WF
    Chu, KC
    Chatterjee, N
    Brawley, O
    Brinton, LA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 18 - 27
  • [2] Barrios Enrique, 2017, Anfamed, V4, P7, DOI 10.25184/anfamed2017.4.1.2
  • [3] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
    Baselga, Jose
    Perez, Edith A.
    Pienkowski, Tadeusz
    Bell, Richard
    [J]. ONCOLOGIST, 2006, 11 : 4 - 12
  • [4] Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations
    Camejo, Natalia
    Castillo, Cecilia
    Alonso, Rafael
    Correa, Fernando
    Rivero, Emiliano
    Mezquita, Camila
    Rosich, Agustin
    Dellacasa, Fiamma
    Silveira, Luciana
    Delgado, Lucia
    [J]. JCO GLOBAL ONCOLOGY, 2020, 6 : 217 - 223
  • [5] Camejo Natalia, 2015, Arch Med Int, V37, P109
  • [6] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    Cameron, David
    Piccart-Gebhart, Martine J.
    Gelber, Richard D.
    Procter, Marion
    Goldhirsch, Aron
    de Azambuja, Evandro
    Castro, Gilberto, Jr.
    Untch, Michael
    Smith, Ian
    Gianni, Luca
    Baselga, Jose
    Al-Sakaff, Nedal
    Lauer, Sabine
    McFadden, Eleanor
    Leyland-Jones, Brian
    Bell, Richard
    Dowsett, Mitch
    Jackisch, Christian
    [J]. LANCET, 2017, 389 (10075) : 1195 - 1205
  • [7] Comision Honoraria de Lucha contra el Cancer, ANN REP PER 2012 201
  • [8] Conzen SD., 2008, DEVITA, V8th ed, P1595
  • [9] Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management
    Curigliano, Giuseppe
    Cardinale, Daniela
    Dent, Susan
    Criscitiello, Carmen
    Aseyev, Olexiy
    Lenihan, Daniel
    Cipolla, Carlo Maria
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (04) : 310 - 325
  • [10] Gómez Andreina, 2019, Rev.Urug.Cardiol., V34, P85, DOI 10.29277/cardio.34.1.8